Premium Nahrungsergänzungsmittel | artgerecht

Autoimmune Hemolytic Anemia – Causes and Treatment

Autoimmune hemolytic anemia (AIHA) is a condition in which the immune system mistakenly destroys the body's own red blood cells, leading to anemia with symptoms such as fatigue, pallor, and shortness of breath.

Regular tips about health Regular tips about health

Things worth knowing about "Autoimmune Hemolytic Anemia"

Autoimmune hemolytic anemia (AIHA) is a condition in which the immune system mistakenly destroys the body's own red blood cells, leading to anemia with symptoms such as fatigue, pallor, and shortness of breath.

What is Autoimmune Hemolytic Anemia?

Autoimmune hemolytic anemia (AIHA) is a form of anemia in which the body's immune system produces antibodies that mistakenly target and destroy its own red blood cells (erythrocytes). This premature destruction of red blood cells is called hemolysis. When red blood cells are broken down faster than the bone marrow can replace them, the oxygen-carrying capacity of the blood decreases, resulting in anemia.

Causes and Types

AIHA is classified based on the type of antibodies involved and the temperature at which they are most active:

Warm AIHA (most common type): Antibodies (usually IgG) are active at normal body temperature (37 °C / 98.6 °F). It can be idiopathic (no identifiable cause) or secondary to conditions such as systemic lupus erythematosus, chronic lymphocytic leukemia, or certain medications.
Cold AIHA (cold agglutinin disease): Antibodies (usually IgM) become active at lower temperatures. This type is often triggered by infections such as Mycoplasma pneumoniae or Epstein-Barr virus, or may be associated with lymphoproliferative disorders.
Paroxysmal cold hemoglobinuria (PCH): A rare form occurring mainly in children, often following a viral infection.

Symptoms

Symptoms vary depending on the severity and speed of red blood cell destruction. Common signs include:

Fatigue and general weakness
Pallor of the skin and mucous membranes
Shortness of breath, especially during physical activity
Rapid heartbeat (tachycardia)
Yellowing of the skin and eyes (jaundice), caused by elevated bilirubin levels
Dark (brownish-red) urine due to the presence of hemoglobin
Enlarged spleen (splenomegaly)

Diagnosis

The diagnosis of AIHA is based on a combination of clinical findings and laboratory tests:

Complete blood count (CBC): Shows anemia with an elevated reticulocyte count (reticulocytosis), indicating increased red blood cell production by the bone marrow.
Direct Antiglobulin Test (DAT / Coombs test): The key confirmatory test. It detects antibodies or complement proteins attached to the surface of red blood cells.
Laboratory markers of hemolysis: Elevated indirect bilirubin, elevated LDH (lactate dehydrogenase), and reduced haptoglobin levels.
Peripheral blood smear to identify abnormal cell shapes (e.g., spherocytes).

Treatment

Treatment depends on the type and severity of AIHA, as well as any underlying condition:

Medical Therapy

Corticosteroids (e.g., prednisolone): First-line treatment for warm AIHA. They suppress the immune response and reduce antibody production.
Rituximab: A monoclonal antibody targeting B-cells, used when corticosteroids are insufficient or in cases of relapse.
Immunosuppressive agents (e.g., azathioprine, mycophenolate mofetil): Used in chronic or refractory cases.

Additional Measures

Splenectomy (surgical removal of the spleen): May be considered in treatment-resistant warm AIHA, as the spleen is the primary site where antibody-coated red blood cells are destroyed.
Blood transfusions: Used as a bridging measure in severe, life-threatening anemia.
Treatment of the underlying disease in secondary AIHA.

Prognosis and Outlook

The course of AIHA varies widely between individuals. Some patients achieve complete remission, while others experience a chronic, relapsing course. Regular medical follow-up is essential to detect and manage flares early. The overall prognosis depends largely on the underlying cause and the response to treatment.

References

Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010;116(11):1831-1838.
Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258-271.
Swiecicki PL, Hegerova LT, Gertz MA. Cold agglutinin disease. Blood. 2013;122(7):1114-1121.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.